Magnesium in the CNS: recent advances and developments.
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical and experimental studies without systematic search or human clinical trials data presented.
PubMed 27829572 · doi:10.1684/mrh.2016.0408
What was done
This narrative review synthesized experimental literature on the neuroprotective role of magnesium across various central nervous system conditions (including headache, stress, acute brain injury, seizures, Parkinson's disease, and Alzheimer's disease), focusing on delivery strategies to overcome blood-brain barrier permeability limitations.
What was found
The abstract provides no quantitative metrics or effect sizes. It notes that standard magnesium salt administration often fails therapeutically due to limited blood-brain barrier penetration. Experimental approaches utilizing carriers (such as polyethylene glycol) reduced the necessary systemic magnesium dose and limited peripheral adverse effects, while permeable formulations such as magnesium threonate demonstrated positive outcomes in preclinical Alzheimer's disease models.
Why it matters
Effective central nervous system penetration is a primary hurdle in translating magnesium's neuroprotective properties into clinical practice. Identifying formulation strategies that enhance blood-brain barrier transport could guide more effective dosing and trial design for neurological disorders.
Limits
The review relies on experimental and animal models rather than clinical trial data. No systematic search methodology, quantitative meta-analysis, or specific numerical data points were provided in the abstract.
Cited by
- supports Magnesium L-threonate crosses the blood-brain barrier more readily than other forms of magnesium in animal models.